Axogen, Inc. (NASDAQ:AXGN) stock is trading lower on Thursday with a session volume of 1.92 million compared to the average volume of 885.013 thousand.
Axogen’s 52-week stock range falls between $9.215 and $34.705, according to Benzinga Pro data.
On Wednesday, Axogen priced its upsized underwritten public offering of 4 million shares at $31.00 per share, which is expected to generate approximately $124 million in gross proceeds.
The company plans to use the net proceeds from this offering for early payoff of its term loan facility, working capital, and other general corporate purposes. This move indicates a strategic effort to strengthen its financial position and support growth initiatives.
In December 2025, the U.S. Food and Drug Administration (FDA) approved Axogen’s Biologics License Application for Avance, an acellular nerve scaffold for adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities.
Axogen’s Technical Indicators Overview
The stock is currently trading 9.8% below its 20-day simple moving average (SMA) but is 31.4% above its 100-day SMA, demonstrating longer-term strength. Over the past 12 months, shares have increased 74.75% and are currently positioned closer to their 52-week highs than lows.
The RSI is at 59.14, which is considered neutral territory. Meanwhile, MACD is below its signal line, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $34.50
- Key Support: $30.50
Analyst Consensus & Recent Actions:
The stock carries a Buy Rating with an average price target of $27.79. Recent analyst moves include:
- Canaccord Genuity: Buy (Raises Target to $37.00)
- HC Wainwright & Co.: Buy (Raises Target to $39.00)
- Jefferies: Buy (Raises Target to $36.00)
Axogen’s Benzinga Edge Scorecard Analysis
Below is the Benzinga Edge scorecard for Axogen, highlighting its strengths and weaknesses compared to the broader market:
- Value Rank: 8.33 — The stock is trading at a premium relative to peers.
- Momentum Rank: 96.05 — The stock is outperforming the broader market.
The Verdict: Axogen’s Benzinga Edge signal reveals a strong momentum setup. While the Value score indicates some risk, the high Momentum score suggests that the stock is currently in a favorable trading position.
ETFs with Significant AXGN Holdings
- State Street SPDR S&P Health Care Equipment ETF (NYSE:XHE): 1.83% Weight
- SPDR S&P Health Care Equipment ETF (NYSE:XHE): 1.91% Weight
- ROBO Global Healthcare Technology and Innovation ETF (NYSE:HTEC): 3.56% Weight
Significance: Because AXGN carries significant weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.
AXGN Price Action: Axogen shares were down 2.21% at $32.28 at the time of publication on Thursday. The stock is approaching its 52-week high of $34.70, according to Benzinga Pro data.
Image via Shutterstock
